247 related articles for article (PubMed ID: 20712376)
1. Characterization of the interactions of vMIP-II, and a dimeric variant of vMIP-II, with glycosaminoglycans.
Zhao B; Liwang PJ
Biochemistry; 2010 Aug; 49(33):7012-22. PubMed ID: 20712376
[TBL] [Abstract][Full Text] [Related]
2. Importance of basic residues and quaternary structure in the function of MIP-1 beta: CCR5 binding and cell surface sugar interactions.
Laurence JS; Blanpain C; De Leener A; Parmentier M; LiWang PJ
Biochemistry; 2001 Apr; 40(16):4990-9. PubMed ID: 11305915
[TBL] [Abstract][Full Text] [Related]
3. Biophysical and Computational Studies of the vCCI:vMIP-II Complex.
Nguyen AF; Kuo NW; Showalter LJ; Ramos R; Dupureur CM; Colvin ME; LiWang PJ
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28813018
[TBL] [Abstract][Full Text] [Related]
4. Dynamics study on the anti-human immunodeficiency virus chemokine viral macrophage-inflammatory protein-II (VMIP-II) reveals a fully monomeric protein.
LiWang AC; Cao JJ; Zheng H; Lu Z; Peiper SC; LiWang PJ
Biochemistry; 1999 Jan; 38(1):442-53. PubMed ID: 9890927
[TBL] [Abstract][Full Text] [Related]
5. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Zhou N; Luo Z; Luo J; Hall JW; Huang Z
Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
[TBL] [Abstract][Full Text] [Related]
6. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
7. The binding surface and affinity of monomeric and dimeric chemokine macrophage inflammatory protein 1 beta for various glycosaminoglycan disaccharides.
McCornack MA; Cassidy CK; LiWang PJ
J Biol Chem; 2003 Jan; 278(3):1946-56. PubMed ID: 12411442
[TBL] [Abstract][Full Text] [Related]
8. CCR2 and CCR5 receptor-binding properties of herpesvirus-8 vMIP-II based on sequence analysis and its solution structure.
Shao W; Fernandez E; Sachpatzidis A; Wilken J; Thompson DA; Schweitzer BI; Lolis E
Eur J Biochem; 2001 May; 268(10):2948-59. PubMed ID: 11358512
[TBL] [Abstract][Full Text] [Related]
9. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines.
Dairaghi DJ; Fan RA; McMaster BE; Hanley MR; Schall TJ
J Biol Chem; 1999 Jul; 274(31):21569-74. PubMed ID: 10419462
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the structure of vMIP-II with eotaxin-1, RANTES, and MCP-3 suggests a unique mechanism for CCR3 activation.
Fernandez EJ; Wilken J; Thompson DA; Peiper SC; Lolis E
Biochemistry; 2000 Oct; 39(42):12837-44. PubMed ID: 11041848
[TBL] [Abstract][Full Text] [Related]
11. Solution NMR characterization of chemokine CXCL8/IL-8 monomer and dimer binding to glycosaminoglycans: structural plasticity mediates differential binding interactions.
Joseph PR; Mosier PD; Desai UR; Rajarathnam K
Biochem J; 2015 Nov; 472(1):121-33. PubMed ID: 26371375
[TBL] [Abstract][Full Text] [Related]
12. The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization.
Dyer DP; Salanga CL; Volkman BF; Kawamura T; Handel TM
Glycobiology; 2016 Mar; 26(3):312-26. PubMed ID: 26582609
[TBL] [Abstract][Full Text] [Related]
13. Glycosaminoglycan disaccharide alters the dimer dissociation constant of the chemokine MIP-1 beta.
McCornack MA; Boren DM; LiWang PJ
Biochemistry; 2004 Aug; 43(31):10090-101. PubMed ID: 15287737
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of viral macrophage inflammatory protein I encoded by Kaposi's sarcoma-associated herpesvirus at 1.7A.
Luz JG; Yu M; Su Y; Wu Z; Zhou Z; Sun R; Wilson IA
J Mol Biol; 2005 Oct; 352(5):1019-28. PubMed ID: 16140327
[TBL] [Abstract][Full Text] [Related]
15. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta.
Koopmann W; Ediriwickrema C; Krangel MS
J Immunol; 1999 Aug; 163(4):2120-7. PubMed ID: 10438952
[TBL] [Abstract][Full Text] [Related]
16. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II.
Luo Z; Fan X; Zhou N; Hiraoka M; Luo J; Kaji H; Huang Z
Biochemistry; 2000 Nov; 39(44):13545-50. PubMed ID: 11063591
[TBL] [Abstract][Full Text] [Related]
17. Identification of a glycosaminoglycan binding surface on human interleukin-8.
Kuschert GS; Hoogewerf AJ; Proudfoot AE; Chung CW; Cooke RM; Hubbard RE; Wells TN; Sanderson PN
Biochemistry; 1998 Aug; 37(32):11193-201. PubMed ID: 9698365
[TBL] [Abstract][Full Text] [Related]
18. The Anti-inflammatory Protein TSG-6 Regulates Chemokine Function by Inhibiting Chemokine/Glycosaminoglycan Interactions.
Dyer DP; Salanga CL; Johns SC; Valdambrini E; Fuster MM; Milner CM; Day AJ; Handel TM
J Biol Chem; 2016 Jun; 291(24):12627-12640. PubMed ID: 27044744
[TBL] [Abstract][Full Text] [Related]
19. NMR structures of anti-HIV D-peptides derived from the N-terminus of viral chemokine vMIP-II.
Mori M; Liu D; Kumar S; Huang Z
Biochem Biophys Res Commun; 2005 Sep; 335(3):651-8. PubMed ID: 16115468
[TBL] [Abstract][Full Text] [Related]
20. The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Delta3 vectors.
Morris KV; Higgins J; Shen X; Stine JT; Pedersen NC
Virus Res; 2003 Aug; 94(2):103-12. PubMed ID: 12902039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
